AZTherapies gets FDA nod to initiate Phase III trial of ALZT-OP1 to treat Alzheimer's disease

US-based AZTherapies has received clearance from the US Food and Drug Administration (FDA) to proceed with the Phase III clinical trial submitted in its investigational new drug (IND) application.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news